Navigation Links
Can two killers make a cure?

Regulators in the US could soon be asked to approve a human trial of gene therapy for cystic fibrosis that uses a hybrid of the HIV and Ebola viruses. Tests on monkeys show the hybrid virus delivers genes to the lungs far more efficiently than any other method developed so far. And while the idea of combining two killer viruses sounds horrifying, the risks should be low.

Despite much effort, no one has managed to develop an effective form of gene therapy to treat the lung problems of people with cystic fibrosis. The condition is caused by a mutation in the CFTR gene, and one of the problems in developing a treatment is getting a working version of CFTR into a high enough proportion of cells to restore normal lung function.

While HIV is good at adding genes to cells' genomes, it does not target lung epithelial cells. Ebola binds strongly to these cells, so Gary Kobinger at the University of Pennsylvania in Philadelphia tried adding a surface protein from Ebola to HIV. Initial tests on mice showed the hybrid virus was very efficient: the gene it carried was active in 24 per cent of airway cells after two months, a far better proportion than achieved by other delivery methods (New Scientist, 10 March 2001, p 19).

But will it work in humans? The team has now done the next best thing and used the hybrid virus to deliver a test gene, lacZ, to the lungs of monkeys. After two months the gene was active in 21 per cent of cells, Kobinger told New Scientist. He is preparing the results for publication.

"The gap between monkeys and humans is much smaller than from mice to monkeys," says Ray Pickles, a gene therapy researcher at the University of North Carolina, Chapel Hill. "This could be in human trials pretty soon."

Kobinger now plans a more extensive monkey trial to convince the US Food and Drug Administration that human trials will be safe. The hybrid virus is created by adding HIV RNA, a stripped-down version of the Ebola surface prot ein RNA and the therapeutic gene to cells. The hybrid virus then self-assembles. Crucially, only the therapeutic gene is incorporated into the hybrid virus, so it cannot replicate.

All attempts in the lab to force such viruses to regain the ability to replicate have failed. Even if this did happen in the body, the resulting virus would resemble HIV, as the hybrid contains no Ebola genes - and HIV cannot infect lung cells. If it did get into the blood, where normal HIV thrives, such a virus would not replicate as efficiently as wild-type HIV. While the patient might suffer, the virus could never reach high enough levels in the body to infect others, Pickles says.

The biggest risk is that if a patient becomes infected with wild-type HIV, the wild-type virus and the hybrid could somehow merge, but such recombination has never been observed in HIV.

Despite his confidence that the hybrid will be safe, Pickles has abandoned similar research as he fears opposition from a fearful public will prevent the method ever being used. Another problem with Kobinger's approach is that patients will require repeated treatments, because the added gene ends up in surface cells that die off after a few months. Other teams are trying to find ways of targeting the progenitor cells that give rise to the surface cells.


'"/>

Source:New Scientist Boston office


Related biology news :

1. Thinking the pain away? Study shows the brains painkillers may cause placebo effect
2. Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack
3. Brazilians sequence genes of pig and poultry killers
4. A new target for painkillers
5. FDA causes unnecessary scare about common painkillers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/4/2017)... the thousands of attendees at this year,s International Consumer Electronics Show (CES), ... measurement devices and services, will be featuring its new line of ULTRA ... special CES Exhibit Suite , the new upper arm and wrist ... WellnessConnected product platform.  Continue Reading ... ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... 23, 2017  Alkahest Inc. ("Alkahest"), a biotechnology ... diseases and other age-related conditions, announced today that Sam ... Chief Medical Officer. In this role, Dr. Jackson ... at Alkahest and serve on the Executive Leadership ... as Executive Director at Dynavax, where he led the ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... ongoing endeavors to bring to market a pioneering medical device for the treatment ... signed an engagement contract with Emergo, a global regulatory consultancy that helps companies ...
(Date:1/20/2017)... , ... January 20, 2017 , ... The two newest ... treatment options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, ... lab space at 3624 Market Street. , Vironika is developing a treatment for ...
Breaking Biology Technology: